There are gaps in research regarding the impact of systemic insulin in T2DM animal models and its comparison with outcomes in T1DM, highlighting the need for future studies to consider diabetes pathophysiology and drug mechanisms to evaluate effectiveness, safety, and influence on implant osseointegration. This evidence concerns the gene INS and type 1 diabetes mellitus.